Technical Analysis for AZN - Astrazeneca PLC

Grade Last Price % Change Price Change
grade A 44.61 2.39% 1.04
AZN closed up 2.39 percent on Thursday, September 19, 2019, on 1.2 times normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AZN trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Doji - Bearish? Reversal 0.00%
Gapped Up Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 50 DMA Bullish 2.39%
Stochastic Buy Signal Bullish 2.39%
Gapped Up Strength 2.39%
Doji - Bearish? Reversal 3.43%
Lower Bollinger Band Walk Weakness 3.43%
Oversold Stochastic Weakness 3.43%

Older signals for AZN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. Its principal products include Atacand for hypertension and heart failure; Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure, and angina; Nexium for acid reflux; Synagis for RSV, a respiratory infection in infants; Seroquel IR for schizophrenia and bipolar disorders; and Seroquel XR for schizophrenia, bipolar disorder, and major depressive disorders. The company principal products also comprise Zoladex for prostate and breast cancer; Pulmicort for asthma and chronic obstructive pulmonary diseases; and Symbicort for asthma and chronic obstructive pulmonary diseases. In addition, it has 84 pipeline projects, which include 71 projects in various clinical phases of development. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc. to develop and commercialize monoclonal antibodies; Ironwood Pharmaceuticals, Inc to co-develop and co-commercialize linaclotide in China; BIND Therapeutics, Inc. to develop and commercialize cancer nanomedicine; and WuXi AppTec to develop and commercialize MEDI5117, a biologic for autoimmune and inflammatory diseases. It also has a strategic alliance with Isis Pharmaceuticals, Inc. for the discovery and development of novel generation antisense therapeutics; and a strategic collaboration with FibroGen, Inc. to develop and commercialize FG-4592, a compound for the treatment of anemia associated with chronic kidney disease and end-stage renal disease. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.
Cancer Drugs Antibodies Monoclonal Antibodies Infection Breast Cancer Neuroscience Schizophrenia Asthma Chronic Kidney Disease Heart Failure Hypertension Psychoactive Drugs Anemia End Stage Renal Disease Astrazeneca Autoimmune And Inflammatory Diseases Pulmonology Angina Bipolar Disorder Chronic Condition Chronic Obstructive Pulmonary Diseases Major Depressive Disorders Respiratory Disease Södertälje Municipality Bipolar Disorders Ironwood Pharmaceuticals
Is AZN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 45.69
52 Week Low 35.3
Average Volume 3,453,174
200-Day Moving Average 40.3064
50-Day Moving Average 43.4076
20-Day Moving Average 44.236
10-Day Moving Average 43.44
Average True Range 0.7061
ADX 22.42
+DI 30.3325
-DI 29.6435
Chandelier Exit (Long, 3 ATRs ) 43.5717
Chandelier Exit (Short, 3 ATRs ) 44.3083
Upper Bollinger Band 46.1629
Lower Bollinger Band 42.3091
Percent B (%b) 0.6
BandWidth 8.711909
MACD Line -0.1037
MACD Signal Line 0.018
MACD Histogram -0.1217
Fundamentals Value
Market Cap 112.96 Billion
Num Shares 2.53 Billion
EPS 1.52
Price-to-Earnings (P/E) Ratio 29.35
Price-to-Sales 3.91
Price-to-Book 6.22
PEG Ratio 2.37
Dividend 0.90
Dividend Yield 2.02%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.24
Resistance 3 (R3) 45.25 45.05 45.14
Resistance 2 (R2) 45.05 44.89 45.05 45.10
Resistance 1 (R1) 44.83 44.79 44.73 44.82 45.06
Pivot Point 44.63 44.63 44.58 44.63 44.63
Support 1 (S1) 44.41 44.47 44.31 44.40 44.16
Support 2 (S2) 44.21 44.37 44.21 44.12
Support 3 (S3) 43.99 44.21 44.09
Support 4 (S4) 43.98